Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma

Abstract Background Immunotherapy is an important treatment in oncology, but only a fraction of patients with head and neck squamous cell carcinoma (HNSCC) benefit from it. Therefore, the aim of this study was to identify predictive biomarkers of immunotherapy response for HNSCC in order to improve...

Full description

Bibliographic Details
Main Authors: Xuanli Xu, Rongrong Li, Lin Zhang, Guopei Zhu, Dandan Ren, Lijia Wu, Xiaoli Gong
Format: Article
Language:English
Published: BMC 2021-11-01
Series:Diagnostic Pathology
Subjects:
Online Access:https://doi.org/10.1186/s13000-021-01147-7
_version_ 1818429788262498304
author Xuanli Xu
Rongrong Li
Lin Zhang
Guopei Zhu
Dandan Ren
Lijia Wu
Xiaoli Gong
author_facet Xuanli Xu
Rongrong Li
Lin Zhang
Guopei Zhu
Dandan Ren
Lijia Wu
Xiaoli Gong
author_sort Xuanli Xu
collection DOAJ
description Abstract Background Immunotherapy is an important treatment in oncology, but only a fraction of patients with head and neck squamous cell carcinoma (HNSCC) benefit from it. Therefore, the aim of this study was to identify predictive biomarkers of immunotherapy response for HNSCC in order to improve treatment outcomes. Methods Survival analyses and comparative efficacy evaluation were performed to investigate prognostic and therapeutic impact factors in patients with advanced HNSCC following immunotherapy, and to examine the effects of factors including gene mutations, tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and immune cell infiltration on the survival and efficacy. Results Anti-PD-1 treatment led to a prolonged overall survival (OS) in HNSCC patients with gene mutations compared with those without the mutations, while no significant difference in the OS was found between the two groups of patients. And no marked association between the MATH value and OS was detected in HNSCC patients, whereas patients with either high TMB scores in tissues and blood or high immune cell infiltration displayed a significantly longer OS. Further analysis with efficacy as the primary endpoint revealed no significant differences in the tissue TMB, blood TMB, and MATH value between the patients who responded to immunotherapy and those who did not. Moreover, no significant differences in the expression percentages of positive immune cells in tumor, stroma, and total regions were identified between the above two groups of patients. Conclusion HNSCC is characterized by high mutation rate, high mutation burden, and high level of immune cell infiltration, and a subset of HNSCC patients respond to immunotherapy. Here, we showed that high mutation burden and immune cell infiltration may improve the prognosis of HNSCC patients with immunotherapy, while there was no remarkable effect on the efficacy.
first_indexed 2024-12-14T15:23:05Z
format Article
id doaj.art-7c767f7a3a1e4b3fb853351e46948a2e
institution Directory Open Access Journal
issn 1746-1596
language English
last_indexed 2024-12-14T15:23:05Z
publishDate 2021-11-01
publisher BMC
record_format Article
series Diagnostic Pathology
spelling doaj.art-7c767f7a3a1e4b3fb853351e46948a2e2022-12-21T22:56:05ZengBMCDiagnostic Pathology1746-15962021-11-0116111110.1186/s13000-021-01147-7Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinomaXuanli Xu0Rongrong Li1Lin Zhang2Guopei Zhu3Dandan Ren4Lijia Wu5Xiaoli Gong6Department of Oral and Maxillofacial Head and Neck Oncology, the Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of MedicineDepartment of Oral and Maxillofacial Head and Neck Oncology, the Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of MedicineDepartment of Oral and Maxillofacial Head and Neck Oncology, the Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of MedicineDepartment of Oral and Maxillofacial Head and Neck Oncology, the Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of MedicineGenecast Biotechnology Co., LtdGenecast Biotechnology Co., LtdGenecast Biotechnology Co., LtdAbstract Background Immunotherapy is an important treatment in oncology, but only a fraction of patients with head and neck squamous cell carcinoma (HNSCC) benefit from it. Therefore, the aim of this study was to identify predictive biomarkers of immunotherapy response for HNSCC in order to improve treatment outcomes. Methods Survival analyses and comparative efficacy evaluation were performed to investigate prognostic and therapeutic impact factors in patients with advanced HNSCC following immunotherapy, and to examine the effects of factors including gene mutations, tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and immune cell infiltration on the survival and efficacy. Results Anti-PD-1 treatment led to a prolonged overall survival (OS) in HNSCC patients with gene mutations compared with those without the mutations, while no significant difference in the OS was found between the two groups of patients. And no marked association between the MATH value and OS was detected in HNSCC patients, whereas patients with either high TMB scores in tissues and blood or high immune cell infiltration displayed a significantly longer OS. Further analysis with efficacy as the primary endpoint revealed no significant differences in the tissue TMB, blood TMB, and MATH value between the patients who responded to immunotherapy and those who did not. Moreover, no significant differences in the expression percentages of positive immune cells in tumor, stroma, and total regions were identified between the above two groups of patients. Conclusion HNSCC is characterized by high mutation rate, high mutation burden, and high level of immune cell infiltration, and a subset of HNSCC patients respond to immunotherapy. Here, we showed that high mutation burden and immune cell infiltration may improve the prognosis of HNSCC patients with immunotherapy, while there was no remarkable effect on the efficacy.https://doi.org/10.1186/s13000-021-01147-7Head and neck squamous cell carcinomaImmunotherapyPrognosisEfficacy
spellingShingle Xuanli Xu
Rongrong Li
Lin Zhang
Guopei Zhu
Dandan Ren
Lijia Wu
Xiaoli Gong
Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
Diagnostic Pathology
Head and neck squamous cell carcinoma
Immunotherapy
Prognosis
Efficacy
title Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_full Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_fullStr Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_full_unstemmed Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_short Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_sort identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
topic Head and neck squamous cell carcinoma
Immunotherapy
Prognosis
Efficacy
url https://doi.org/10.1186/s13000-021-01147-7
work_keys_str_mv AT xuanlixu identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma
AT rongrongli identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma
AT linzhang identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma
AT guopeizhu identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma
AT dandanren identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma
AT lijiawu identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma
AT xiaoligong identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma